Eisai Submits Application for Additional Indication of Anticancer Agent Lenvima for Hepatocellular Carcinoma in Japan

Eisai Co., Ltd. announced that it has submitted an application for an additional indication of its in-house discovered and developed anticancer agent Lenvima for the treatment of hepatocellular carcinoma (HCC) in Japan, the first in the world.

Technology selection identified as biggest hurdle in serialization race for compliance

New industry research explores the greatest barriers to serialization success as companies across the pharmaceutical supply chain prepare for new regulations in the US and Europe. ...

Juniper Pharma Services Brings PSD-1 Spray Dryer Online

Juniper Pharma Services has broadened its manufacturing capabilities bringing on-line its new spray dryer following the successful installation and validation of the advanced manufacturing equipment at its UK-based site.

Boston Biomedical Announces Unblinding of the Phase 3 Trial in Patients with Advanced Gastric/GEJ Cancer

Boston Biomedical Inc, announced that the BRIGHTER Trial evaluating the efficacy and safety of napabucasin plus paclitaxel versus paclitaxel alone for patients with advanced gastric/GEJ cancer will be unblinded..

LANXESS expects best results in company history in 2017

pecialty chemicals company LANXESS projects the highest full year results in company history, following a very strong first quarter of 2017 and the successful closing of the acquisition of U.S. based company Chemtura. Global sales of the specialty...

BioGeneration Ventures Fund III Secures EUR 66m, exceeding EUR 50m target

BioGeneration Ventures , the early stage life sciences venture capital firm with funds focussed on European biotechnology companies, announces an investment by the European Investment Fund...

For Advertising Queries:

Please e-mail : kathryn@worldpharmatoday.com
or
call to: + 91 88268 49084

If you like to receive our latest Media Pack 2017 / Editorial Calender please click here

For the latest visit: www.worldpharmatoday.com